Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.vaccine.2011.10.088
Title: Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine
Authors: Tambyah, P.A. 
Wilder-Smith, A. 
Pavlova, B.G.
Barrett, P.N.
Oh, H.M.L.
Hui, D.S.
Yuen, K.-Y.
Fritsch, S.
Aichinger, G.
Loew-Baselli, A.
van der Velden, M.
Maritsch, F.
Kistner, O.
Ehrlich, H.J.
Keywords: Avian influenza
H5N1
Immunogenicity
Pandemic vaccine
PHASE I/II
Pre-pandemic vaccine
Safety
Issue Date: 5-Jan-2012
Citation: Tambyah, P.A., Wilder-Smith, A., Pavlova, B.G., Barrett, P.N., Oh, H.M.L., Hui, D.S., Yuen, K.-Y., Fritsch, S., Aichinger, G., Loew-Baselli, A., van der Velden, M., Maritsch, F., Kistner, O., Ehrlich, H.J. (2012-01-05). Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30 (2) : 329-335. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2011.10.088
Abstract: A successful vaccine development strategy for areas with clustered H5N1 events requires conduct of vaccine trials in potentially non-naïve subjects and evaluation of post-vaccination responsiveness. An open-label, randomized, phase I/II study therefore assessed the immunogenicity and safety of two different dose levels of an inactivated, non-adjuvanted, whole virus clade 2.1 (A/Indonesia/05/2005) H5N1 Vero cell-derived influenza vaccine in healthy adults (21-45 years) from a region where the virus has been circulating (Hong Kong) as well as Singapore. Subjects (N=110) were randomized 1:1 to receive two vaccinations with either 3.75μg or 7.5μg H5N1 haemagglutinin antigen 21 days apart. Safety, immunogenicity (microneutralization [MN] and single radial haemolysis [SRH] at baseline and post-vaccination) and cross-reactivity against a heterologous clade 1 strain (A/Vietnam/1203/2004) of the vaccine were assessed. Pre-existing immunity to the vaccine strain was 14% which is higher than previously reported for these regions. Two vaccinations with either vaccine formulation induced high seroprotection rates (MN titre ≥ 1:20) against the vaccine strain A/Indonesia/05/2005: 82.7% and 86.5% in the 3.75μg and 7.5μg dose groups. Seroconversion rates and fold increase exceeded the CPMP criterion of >40% and >2.5 for MN and SRH in both dose groups after the second vaccination, while the seroprotection rate in the 7.5μg dose group determined by SRH was only marginally lower (69.2%) than the CPMP criterion of >70%. Thus, 11 of 12 CHMP criteria were fulfilled. A cross-reactive antibody response against the heterologous A/Vietnam/1203/2004 strain was demonstrated after the second vaccination (>21% by MN and ≥25% by SRH). Persistence of antibodies against the vaccine strain was also demonstrated 6 months after the first vaccination, indicating that a booster vaccination would be effective in those who have received two priming doses. No serious adverse events were reported. The H5N1 influenza vaccine against clade 2.1 strain A/Indonesia/05/2005 was well tolerated and immunogenic after two vaccinations, and induced a cross-neutralizing antibody response, with no dose effect. © 2011 Elsevier Ltd.
Source Title: Vaccine
URI: http://scholarbank.nus.edu.sg/handle/10635/126850
ISSN: 0264410X
DOI: 10.1016/j.vaccine.2011.10.088
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

19
checked on Dec 15, 2019

WEB OF SCIENCETM
Citations

19
checked on Dec 6, 2019

Page view(s)

44
checked on Dec 13, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.